TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04041271

Intervention type: OTHER
Intervention: Cervical range of motion (CROM)
Description: Subjects will perform full-range cervical flexion, extension, side-bending and rotation actively in sitting position. In supine position, cervical flexion-rotation will be performed passively by the assessor.

Intervention type: OTHER
Intervention: Cervical range of motion (CROM)
Description: Subjects will perform full-range cervical flexion, extension, side-bending and rotation actively in sitting position. In supine position, cervical flexion-rotation will be performed passively by the assessor.

Intervention type: OTHER
Intervention: Pressure pain threshold (PPT)
Description: A digital algometer with rubber head will be used to apply pressure on the muscles of subjects. When the subjects start to feel pain, the algometer will be removed immediately.

Intervention type: OTHER
Intervention: Pressure pain threshold (PPT)
Description: A digital algometer with rubber head will be used to apply pressure on the muscles of subjects. When the subjects start to feel pain, the algometer will be removed immediately.

Intervention type: OTHER
Intervention: Cranial-cervical angle (CCA)
Description: Subjects will stand in a relaxed position with colour markers on the earlobe and C7 spinous process. A photo of the head posture will be taken to calculate the included angle between the markers and the horizontal line.

Intervention type: OTHER
Intervention: Cranial-cervical angle (CCA)
Description: Subjects will stand in a relaxed position with colour markers on the earlobe and C7 spinous process. A photo of the head posture will be taken to calculate the included angle between the markers and the horizontal line.

Intervention type: OTHER
Intervention: Jaw kinematics
Description: Jaw kinematics is measured by Ultrasonic Jaw Motion Analyzer (Zebris). The subjects will perform jaw opening, closing, lateral left, lateral right and protrusion for three times.

Intervention type: OTHER
Intervention: Jaw kinematics
Description: Jaw kinematics is measured by Ultrasonic Jaw Motion Analyzer (Zebris). The subjects will perform jaw opening, closing, lateral left, lateral right and protrusion for three times.
Study: NCT04021264

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine-Sufentanil
Description: Local anesthetic injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine-Sufentanil
Description: Local anesthetic injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dextrose 5
Description: Sham injection
Study: NCT04041271

Intervention type: OTHER
Intervention: Muscle activation
Description: Surface electromyography is used to assess the activities of bilateral masseter, anterior temporalis, sternocleidomastoid muscle and upper trapezius. Subjects will perform jaw resting and clenching.

Intervention type: OTHER
Intervention: Muscle activation
Description: Surface electromyography is used to assess the activities of bilateral masseter, anterior temporalis, sternocleidomastoid muscle and upper trapezius. Subjects will perform jaw resting and clenching.
Study: NCT02196935

Intervention type: OTHER
Intervention: clinical course
Description: Detailed presentation including labs, demographics, imaging of those who undergo ERCP/EUS with be prospectively recorded. Details of procedure including sedation strategy and success will be collected. Results of procedure including final pathology results with be recorded.
Study: NCT03479502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Injectable Product
Description: 3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks
Study: NCT03211494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INTELLiVENT-ASV
Description: INTELLiVENT-ASV, with software 2.60

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional lung protective ventilation
Description: Lung protective ventilation according to the ARDSnet guidelines
Study: NCT02219854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Study: NCT03214575

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GPS Method
Study: NCT02999906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Treprostinil
Description: Sustained release oral tablets for three times daily administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sugar pill) for three times daily oral administration
Study: NCT03730532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy Guided Self Help
Description: 6-week manualised Cognitive Behavioural Therapy Guided Self Help

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy Guided Self Help
Description: 6-week manualised Cognitive Behavioural Therapy Guided Self Help

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy Guided Self Help
Description: 6-week manualised Cognitive Analytic Therapy Guided Self Help

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy Guided Self Help
Description: 6-week manualised Cognitive Analytic Therapy Guided Self Help
Study: NCT02917785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karman curettage
Study: NCT04021264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5
Description: Sham injection
Study: NCT01541826

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chokeberry Extract
Description: Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chokeberry extract capsule, acute
Description: Chokeberry extract capsule, 2 x 250 mg, one-time dose.
Study: NCT01565291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi), single dose
Study: NCT04233281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kori tofu
Description: 16.5 gram Kori-tofu mixed in a high carbohydrate test meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: high carbohydrate test meal with whey protein, matched in macronutrient content
Study: NCT02716233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase 1250 IU/m2 x 2
Description: only for ALL of standard risk and medium risk

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegaspargase 2500 IU/m2 x 1
Description: only for ALL of standard risk and medium risk
Study: NCT01289808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose 25%
Description: 1ml of glucose 25% once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose 25%
Description: 1ml glucose once per os
Study: NCT04029467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action
Study: NCT02673775

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clean Air
Description: Subjects will have the clean air exposure first, followed by the ozone exposure
Study: NCT03479502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Injection
Description: 3 intra-articular injections of Doxycycline Injection spaced every two weeks
Study: NCT04617197

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy
Description: Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)
Study: NCT02673775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Subjects will have the ozone exposure first, followed by the clean air exposure
Study: NCT02815228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-034)
Study: NCT01365273

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepitel One
Description: Dressing
Study: NCT04617197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy
Description: Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy
Description: Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)
Study: NCT02406859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bowel Biofeedback
Description: Subjects will complete 2 sessions twice a week for 6 weeks of bowel biofeedback training. Subjects will be asked to squeeze and bear down for a period of 5 seconds followed by rest for 10seconds. Following the training, each subject will complete similar training at home for 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anorectal Manometry
Description: Subjects will undergo an anorectal manometry to establish baseline pressure characteristics. If subjects qualify for biofeedback training, they will complete two additional manometries to track the changes occuring during training.
Study: NCT03474978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripherally Inserted Central Venous Cather (PICC)
Description: Location of the PICC insertion will be randomized and compared

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripherally Inserted Central Venous Cather (PICC)
Description: Location of the PICC insertion will be randomized and compared
Study: NCT03619512

Intervention type: GENETIC
Intervention: Whole exome sequencing.
Description: Retrospective biological exploration of the samples, including tumoral DNA exploration.

Intervention type: GENETIC
Intervention: Whole exome sequencing.
Description: Retrospective biological exploration of the samples, including tumoral DNA exploration.

Intervention type: GENETIC
Intervention: Whole exome sequencing.
Description: Retrospective biological exploration of the samples, including tumoral DNA exploration.

Intervention type: GENETIC
Intervention: Whole exome sequencing.
Description: Retrospective biological exploration of the samples, including tumoral DNA exploration.

Intervention type: GENETIC
Intervention: RNA sequencing
Description: Characterization of tumor transcriptomic profile.

Intervention type: GENETIC
Intervention: RNA sequencing
Description: Characterization of tumor transcriptomic profile.

Intervention type: GENETIC
Intervention: RNA sequencing
Description: Characterization of tumor transcriptomic profile.

Intervention type: GENETIC
Intervention: RNA sequencing
Description: Characterization of tumor transcriptomic profile.

Intervention type: OTHER
Intervention: Mass spectrometry
Description: Characterization of tumor proteomic profiles.

Intervention type: OTHER
Intervention: Mass spectrometry
Description: Characterization of tumor proteomic profiles.

Intervention type: OTHER
Intervention: Mass spectrometry
Description: Characterization of tumor proteomic profiles.

Intervention type: OTHER
Intervention: Mass spectrometry
Description: Characterization of tumor proteomic profiles.
Study: NCT04132206

Intervention type: OTHER
Intervention: stool sampling
Description: Participants will provide two stool samples: one collected the day of inclusion and a second, six months later

Intervention type: OTHER
Intervention: stool sampling
Description: Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
Study: NCT00300261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth monitoring
Description: Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
Study: NCT02905695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chirocaine
Study: NCT02420704

Intervention type: PROCEDURE
Intervention: Embryo transfer
Description: For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.

Intervention type: PROCEDURE
Intervention: Embryo transfer
Description: For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.
Study: NCT02905695

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03780920

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy/osteopathy
Description: In this group, children will benefit from early osteopathic treatment over a period ranging from the third day to 4 months. The number of sessions will not be fixed, on average, 3 sessions will be carried out during this period at the University Hospital of Montpellier.~The duration of the session will be between 20 minutes to 30 or even 40 minutes
Study: NCT02037594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Health Counseling
Description: This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Health Counseling
Description: This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Adherence Intervention
Description: This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Adherence Intervention
Description: This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
Study: NCT03687320

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
Study: NCT04363580

Intervention type: OTHER
Intervention: Auditory processing disorder screening tool
Description: Screening tool : a questionnaire completed by the parents and the child's teacher and a mini-battery of tests composed of verbal and nonverbal assessments.~Questions for parents are grouped into four sections:~* Reference pattern and portrait of the child.~* Auditory history.~* History of speech and language development.~* School history.~The teacher questionnaire has seven sections:~* Portrait of the child.~* Reading and writing.~* Speaking.~* Mathematics.~* Music.~* Memory.~* Listening skills and understanding:~  * Concentration and organization.~ * Environment.~Mini-battery of tests:~* Dichotic Numeric Listening Test.~* Identification test of 15 patterns of frequency-varying sounds at each ear.~* Test of 10 monosyllables in noise per ear.~* Auditory memory test by measuring the range of figures (instead of words in order to reduce the contribution of language processing).
Study: NCT02037594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Information (Active Control)
Description: Standard of Care Information about PrEP

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Information (Active Control)
Description: Standard of Care Information about PrEP
Study: NCT00585910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine and OROS Methylphenidate
Description: Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
Study: NCT00452244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Simvastatin 40mg/QD po daily every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib only
Description: gefitinib 250mg/QD po daily every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib only
Description: gefitinib 250mg/QD po daily every 3 weeks
Study: NCT01163201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treg cells
Description: Given by infusion on Day 0 after transplantation - Five doses of Treg (3 x 10\^6/kg, 10 x 10\^6/kg, 30 x 10\^6/kg, 100 x 10\^6/kg and 300 x 10\^6/kg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3+ Teff cells
Description: Given by infusion on Day 0 after transplantation - 5 doses of CD3+ Teff cells (3 x 10\^6 cells/kg, 6 x 10\^6 cells/kg, 9 x 10\^6 cells/kg, 12 x 10\^6 cells/kg, and 15 x 10\^6 cells/kg with the latter dose representing the median number of CD3+ cells in two UCB unit grafts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given intravenously on Days -8 through -6, 25 mg/m\^2 over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously on Day -7 and -6, 60 mg/kg

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Given on Days -4 through -2, 165 cGY twice a day.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood transplantation
Description: Infusion given on day 0
Study: NCT02420704

Intervention type: PROCEDURE
Intervention: Embryo transfer
Description: For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.
Study: NCT04133012

Intervention type: OTHER
Group type: OTHER
Intervention: Samplings
Description: * blood samples~* rectal biopsies~* nodes biopsies~* cutaneous fat tissues biopsies~* semen sample
Study: NCT04688645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid solution
Description: Balanced crystalloid solution (Plasmalyte) given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 0.9% sodium chloride solution given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
Study: NCT03707626

Intervention type: OTHER
Intervention: Wellens Sign
Description: presence or absence in presence of coronary collaterals to LAD
Study: NCT03926299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FotonaSmooth SP® Spectro laser device
Description: dual laser treatment with thermal Nd:YAG and ablative Er:YAG (Fotona medical device), 4 laser sessions 4-8 weeks apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate 0.05% ointment
Description: 6 months standard treatment with topical steroid cream (high dose for the first two months, medium dose for the next two months, low dose for the last two months)
Study: NCT02033668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK933776 for SQ administration
Description: Antibody solution for subcutaneous injection with unit dose strength of 50mg/mL administered as 200 mg single dose or as repeat dose of 50 mg weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK933776 for SQ administration
Description: Antibody solution for subcutaneous injection with unit dose strength of 50mg/mL administered as 200 mg single dose or as repeat dose of 50 mg weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK933776 for IM administration
Description: Antibody solution for intramuscular injection with unit dose strength of 50mg/mL administered as 200 mg single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK933776 for IV administration
Description: Antibody solution for intravenous injection with unit dose strength of 50mg/mL administered as 200 mg single dose through an IV catheter over approximately 1 hour
Study: NCT00676663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: Entinostat 5 mg tablet orally once per week